Alpha 1-antitrypsin Deficiency (AATD)
3
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Prolastinc 60 Mgkg
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Natural Course and Molecular Basis of Alpha 1- Antitrypsin Deficiency-associated Liver Disease.
Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
Research Network
Common Treatments
- Prolastinc 60 Mgkg1
- Prolastinc 120 Mgkg1
- Blood Sampling1
- Multiomic Spatial Analysis1
Active Sponsors
- PROGENIKA BIOPHARMA, A GRIFOLS Company1
- Grifols Therapeutics LLC1
- Assiut University1
- Muğla Sıtkı Koçman University1
Top Investigators
University of Florida
The University of Texas Health Science Center at Tyler
Temple University Hospital/Temple Lung Center
Medical University of South Carolina, Division of Pulmonary and Critical Care Medicine
Related Conditions
- Emphysema1